Varicella Zoster Infection Treatment Market- Industry Analysis and Forecast (2023-2029)


The Varicella Zoster Infection Treatment Market value is projected to reach US$ 2.15 Bn. at the end of the forecast period and it is expected to grow at the CAGR of 4.12%.

Varicella-zoster virus belongs to α- herpes virus family which is known to infect humans. This virus is present worldwide and is highly infectious. The primary infection causes acute varicella or chickenpox, which commonly affects children, teens, and young adults. The infection is transmitted through direct contact with a skin lesions or through respiratory droplets. After initial infection, this virus establishes lifelong latency in cranial nerve and dorsal root ganglia and can reactivate years later as Herpes zoster or shingles.

Varicella Zoster Infection Treatment Market

To know about the Research Methodology :- Request Free Sample Report

Market Overview:-

The Varicella Zoster Treatment Market is anticipated to grow during the forecast period owing to the key factors such as rising geriatric population, the prevalence of chickenpox and similar diseases. Growing numbers of drugs producing companies along with emerging technologies are expected to create potential opportunities for Varicella Zoster Infection Market.

However, a stringent regulatory approval process may hamper the growth of the market. Along with this, many people rely on alternative medicines made from natural products, which are expected to hamper the antiviral drugs market. Unawareness about Herpes zoster among people in many regions across the globe may also restraint the growth of the market.

Varicella Zoster Infection Treatment Market Segment Analysis:-

By the Drug Type segment, the largest market share is held by Acyclovir as numerous companies manufacture it on large scale. Pricing for this drug is comparatively cheap, hence many physicians prescribe it for the treatment of Varicella Zoster infection. It is expected that acyclovir will hold the largest revenue during the forecast period.

Varicella Zoster Infection Treatment Market Regional Insights:-

The largest share of the Global Varicella-Zoster Treatment Market is held by North America. More than 90% of adults in the United States acquired the disease in childhood, while the majority of children and young adults have been vaccinated with the live virus vaccine.

The objective of the report is to present a comprehensive analysis of the Global Varicella Zoster Infection Treatment Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that includes market leaders, followers, and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analysed, which will give a clear futuristic view of the industry to the decision-makers.

The report also helps in understanding Global Varicella Zoster Infection Treatment Market dynamics, structure by analyzing the market segments and project the Global Varicella Zoster Infection Treatment Marketsize. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Global Varicella Zoster Infection Treatment Market make the report investor’s guide.

Varicella Zoster Infection Treatment Market Scope: Inquire before buying






Varicella Zoster Infection Treatment Market




Report Coverage
Details




Base Year:
2022
Forecast Period:
2023-2029




Historical Data:
2018 to 2022
Market Size in 2022:
US $ 1.62 Bn.




Forecast Period 2023 to 2029 CAGR:
4.12%
Market Size in 2029:
US $ 2.15 Bn.




 Segments Covered:
By Drug Type
Acyclovir
Valacyclovir
Famciclovir




By Route of Administration
oral
Topical
Injectable






Varicella Zoster Infection Market, by region

North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina Rest of South America)

Key players:

1. Dr. Reddy’s Laboratories Ltd.
2. Pfizer Inc.
3. Abbott Laboratories
4. Teva Pharmaceutical Industries Ltd.
5. Mylan N.V.
6. Sun Pharmaceuticals
7. Valeant pharmaceuticals
8. Novartis AG
9. GlaxoSmithKline Plc.
10.Bausch health
11.Merck Sharp & Dohme corp.

Frequently Asked Questions:

1. Which region has the largest share in Varicella Zoster Infection Market?
Ans: North America region held the highest share in 2022.

2. What is the growth rate of Global Varicella Zoster Infection Market?
Ans: The Global Varicella Zoster Infection Market is growing at a CAGR of 4.12% during forecasting period 2023-2029.

3. What is scope of the Global Varicella Zoster Infection market report?
Ans: Global Varicella Zoster Infection Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period.

4. Who are the key players in Global Varicella Zoster Infection market?
Ans: The important key players in the Global Varicella Zoster Infection Market are – Dr. Reddy’s Laboratories Ltd., Pfizer Inc., Abbott Laboratories, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sun Pharmaceuticals, Valeant pharmaceuticals, Novartis AG, GlaxoSmithKline Plc., Bausch health, Merck Sharp & Dohme corp., and

5. What is the study period of this market?
Ans: The Global Varicella Zoster Infection Market is studied from 2022 to 2029. 





Varicella Zoster Infection Treatment Market

1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
1.3. Research Objectives

2. Assumptions and Research Methodology
2.1. Report Assumptions
2.2. Abbreviations
2.3. Research Methodology
2.3.1. Secondary Research
2.3.1.1. Secondary data
2.3.1.2. Secondary Sources
2.3.2. Primary Research
2.3.2.1. Data from Primary Sources
2.3.2.2. Breakdown of Primary Sources

3. Executive Summary: Varicella Zoster Infection Treatment Market Size, by Market Value (US$ Mn)

4. Market Overview
4.1. Introduction
4.2. Market Indicator
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.2.4. Challenges
4.3. Porter’s Analysis
4.4. Value Chain Analysis
4.5. Market Risk Analysis
4.6. SWOT Analysis
4.7. Industry Trends and Emerging Technologies

5. Supply Side and Demand Side Indicators

6. Global Varicella Zoster Infection Treatment Market Analysis and Forecast
6.1. Varicella Zoster Infection Treatment Market Size & Y-o-Y Growth Analysis
6.1.1. North America
6.1.2. Europe
6.1.3. Asia Pacific
6.1.4. Middle East & Africa
6.1.5. South America

7. Global Varicella Zoster Infection Treatment Market Analysis and Forecast, By Drug Type
7.1. Introduction and Definition
7.2. Key Findings
7.3. Varicella Zoster Infection Treatment Market Value Share Analysis, By Drug Type
7.4. Varicella Zoster Infection Treatment Market Size (US$ Mn) Forecast, By Drug Type
7.5. Varicella Zoster Infection Treatment Market Analysis, By Drug Type
7.6. Varicella Zoster Infection Treatment Market Attractiveness Analysis, By Drug Type

8. Global Varicella Zoster Infection Treatment Market Analysis and Forecast, By Route of Administration
8.1. Introduction and Definition
8.2. Key Findings
8.3. Varicella Zoster Infection Treatment Market Value Share Analysis, By Brake Used
8.4. Varicella Zoster Infection Treatment Market Size (US$ Mn) Forecast, By Brake Used
8.5. Varicella Zoster Infection Treatment Market Analysis, By Brake Used
8.6. Varicella Zoster Infection Treatment Market Attractiveness Analysis, By Brake Used

9. Global Varicella Zoster Infection Treatment Market Analysis, by Region
9.1. Varicella Zoster Infection Treatment Market Value Share Analysis, by Region
9.2. Varicella Zoster Infection Treatment Market Size (US$ Mn) Forecast, by Region
9.3. Varicella Zoster Infection Treatment Market Attractiveness Analysis, by Region

10. North America Varicella Zoster Infection Treatment Market Analysis
10.1. Key Findings
10.2. North America Varicella Zoster Infection Treatment Market Overview
10.3. North America Varicella Zoster Infection Treatment Market Value Share Analysis, By Drug Type
10.4. North America Varicella Zoster Infection Treatment Market Forecast, By Drug Type
10.4.1. Acyclovir
10.4.2. Valacyclovir
10.4.3. Famciclovir
10.5. North America Varicella Zoster Infection Treatment Market Value Share Analysis, By Route of Administration
10.6. North America Varicella Zoster Infection Treatment Market Forecast, By Route of Administration
10.6.1. oral
10.6.2. Topical
10.6.3. Injectable
10.7. North America Varicella Zoster Infection Treatment Market Value Share Analysis, by Country
10.8. North America Varicella Zoster Infection Treatment Market Forecast, by Country
10.8.1. U.S.
10.8.2. Canada
10.8.3. Mexico
10.9. North America Varicella Zoster Infection Treatment Market Analysis, by Country
10.10. U.S. Varicella Zoster Infection Treatment Market Forecast, By Drug Type
10.10.1. Acyclovir
10.10.2. Valacyclovir
10.10.3. Famciclovir
10.11. U.S. Varicella Zoster Infection Treatment Market Forecast, By Route of Administration
10.11.1. oral
10.11.2. Topical
10.11.3. Injectable
10.12. Canada Varicella Zoster Infection Treatment Market Forecast, By Drug Type
10.12.1. Acyclovir
10.12.2. Valacyclovir
10.12.3. Famciclovir
10.13. Canada Varicella Zoster Infection Treatment Market Forecast, By Route of Administration
10.13.1. oral
10.13.2. Topical
10.13.3. Injectable
10.14. Mexico Varicella Zoster Infection Treatment Market Forecast, By Drug Type
10.14.1. Acyclovir
10.14.2. Valacyclovir
10.14.3. Famciclovir
10.15. Mexico Varicella Zoster Infection Treatment Market Forecast, By Route of Administration
10.15.1. oral
10.15.2. Topical
10.15.3. Injectable
10.16. North America Varicella Zoster Infection Treatment Market Attractiveness Analysis
10.16.1. By Drug Type
10.16.2. By Route of Administration
10.17. PEST Analysis
10.18. Key Trends
10.19. Key Developments

11. Europe Varicella Zoster Infection Treatment Market Analysis
11.1. Key Findings
11.2. Europe Varicella Zoster Infection Treatment Market Overview
11.3. Europe Varicella Zoster Infection Treatment Market Value Share Analysis, By Drug Type
11.4. Europe Varicella Zoster Infection Treatment Market Forecast, By Drug Type
11.4.1. Acyclovir
11.4.2. Valacyclovir
11.4.3. Famciclovir
11.5. Europe Varicella Zoster Infection Treatment Market Forecast, By Route of Administration
11.5.1. oral
11.5.2. Topical
11.5.3. Injectable
11.6. Europe Varicella Zoster Infection Treatment Market Value Share Analysis, by Country
11.7. Europe Varicella Zoster Infection Treatment Market Forecast, by Country
11.7.1. Germany
11.7.2. U.K.
11.7.3. France
11.7.4. Italy
11.7.5. Spain
11.7.6. Sweden
11.7.7. CIS countries
11.7.8. Rest of Europe
11.8. Germany Varicella Zoster Infection Treatment Market Forecast, By Drug Type
11.8.1. Acyclovir
11.8.2. Valacyclovir
11.8.3. Famciclovir
11.9. Germany Varicella Zoster Infection Treatment Market Forecast, By Route of Administration
11.9.1. oral
11.9.2. Topical
11.9.3. Injectable
11.10. U.K. Varicella Zoster Infection Treatment Market Forecast, By Drug Type
11.10.1. Acyclovir
11.10.2. Valacyclovir
11.10.3. Famciclovir
11.11. U.K. Varicella Zoster Infection Treatment Market Forecast, By Route of Administration
11.11.1. oral
11.11.2. Topical
11.11.3. Injectable
11.12. France Varicella Zoster Infection Treatment Market Forecast, By Drug Type
11.12.1. Acyclovir
11.12.2. Valacyclovir
11.12.3. Famciclovir
11.13. France Varicella Zoster Infection Treatment Market Forecast, By Route of Administration
11.13.1. oral
11.13.2. Topical
11.13.3. Injectable
11.14. Italy Varicella Zoster Infection Treatment Market Forecast, By Drug Type
11.14.1. Acyclovir
11.14.2. Valacyclovir
11.14.3. Famciclovir
11.15. Italy Varicella Zoster Infection Treatment Market Forecast, By Route of Administration
11.15.1. oral
11.15.2. Topical
11.15.3. Injectable
11.16. Spain Varicella Zoster Infection Treatment Market Forecast, By Drug Type
11.16.1. Acyclovir
11.16.2. Valacyclovir
11.16.3. Famciclovir
11.17. Spain Varicella Zoster Infection Treatment Market Forecast, By Route of Administration
11.17.1. oral
11.17.2. Topical
11.17.3. Injectable
11.18. Sweden Varicella Zoster Infection Treatment Market Forecast, By Drug Type
11.18.1. Acyclovir
11.18.2. Valacyclovir
11.18.3. Famciclovir
11.19. Sweden Varicella Zoster Infection Treatment Market Forecast, By Route of Administration
11.19.1. oral
11.19.2. Topical
11.19.3. Injectable
11.20. CIS countries Varicella Zoster Infection Treatment Market Forecast, By Drug Type
11.20.1. Acyclovir
11.20.2. Valacyclovir
11.20.3. Famciclovir
11.21. CIS countries Varicella Zoster Infection Treatment Market Forecast, By Route of Administration
11.21.1. oral
11.21.2. Topical
11.21.3. Injectable
11.22. Rest of Europe Varicella Zoster Infection Treatment Market Forecast, By Drug Type
11.22.1. Acyclovir
11.22.2. Valacyclovir
11.22.3. Famciclovir
11.23. Rest of Europe Varicella Zoster Infection Treatment Market Forecast, By Route of Administration
11.23.1. oral
11.23.2. Topical
11.23.3. Injectable
11.24. Europe Varicella Zoster Infection Treatment Market Attractiveness Analysis
11.24.1. By Route of Administration
11.24.2. By Drug Type
11.25. PEST Analysis
11.26. Key Trends
11.27. Key Developments

12. Asia Pacific Varicella Zoster Infection Treatment Market Analysis
12.1. Key Findings
12.2. Asia Pacific Varicella Zoster Infection Treatment Market Overview
12.3. Asia Pacific Varicella Zoster Infection Treatment Market Value Share Analysis, By Drug Type
12.4. Asia Pacific Varicella Zoster Infection Treatment Market Forecast, By Drug Type
12.4.1. Acyclovir
12.4.2. Valacyclovir
12.4.3. Famciclovir
12.5. Asia Pacific Varicella Zoster Infection Treatment Market Value Share Analysis, By Drug Type
12.6. Asia Pacific Varicella Zoster Infection Treatment Market Forecast, By Route of Administration
12.6.1. oral
12.6.2. Topical
12.6.3. Injectable
12.7. Asia Pacific Varicella Zoster Infection Treatment Market Value Share Analysis, by Country
12.8. Asia Pacific Varicella Zoster Infection Treatment Market Forecast, by Country
12.8.1. China
12.8.2. India
12.8.3. Japan
12.8.4. South Korea
12.8.5. Australia
12.8.6. ASEAN
12.8.7. Rest of Asia Pacific
12.9. Asia Pacific Varicella Zoster Infection Treatment Market Analysis, by Country
12.10. China Varicella Zoster Infection Treatment Market Forecast, By Drug Type
12.10.1. Acyclovir
12.10.2. Valacyclovir
12.10.3. Famciclovir
12.11. China Varicella Zoster Infection Treatment Market Forecast, By Route of Administration
12.11.1. oral
12.11.2. Topical
12.11.3. Injectable
12.12. India Varicella Zoster Infection Treatment Market Forecast, By Drug Type
12.12.1. Acyclovir
12.12.2. Valacyclovir
12.12.3. Famciclovir
12.13. India Varicella Zoster Infection Treatment Market Forecast, By Route of Administration
12.13.1. oral
12.13.2. Topical
12.13.3. Injectable
12.14. Japan Varicella Zoster Infection Treatment Market Forecast, By Drug Type
12.14.1. Acyclovir
12.14.2. Valacyclovir
12.14.3. Famciclovir
12.15. Japan Varicella Zoster Infection Treatment Market Forecast, By Route of Administration
12.15.1. oral
12.15.2. Topical
12.15.3. Injectable
12.16. South Korea Varicella Zoster Infection Treatment Market Forecast, By Drug Type
12.16.1. Acyclovir
12.16.2. Valacyclovir
12.16.3. Famciclovir
12.17. South Korea Varicella Zoster Infection Treatment Market Forecast, By Route of Administration
12.17.1. oral
12.17.2. Topical
12.17.3. Injectable
12.18. Australia Varicella Zoster Infection Treatment Market Forecast, By Drug Type
12.18.1. Acyclovir
12.18.2. Valacyclovir
12.18.3. Famciclovir
12.19. Australia Varicella Zoster Infection Treatment Market Forecast, By Route of Administration
12.19.1. oral
12.19.2. Topical
12.19.3. Injectable
12.20. ASEAN Varicella Zoster Infection Treatment Market Forecast, By Drug Type
12.20.1. Acyclovir
12.20.2. Valacyclovir
12.20.3. Famciclovir
12.21. ASEAN Varicella Zoster Infection Treatment Market Forecast, By Route of Administration
12.21.1. oral
12.21.2. Topical
12.21.3. Injectable
12.22. Rest of Asia Pacific Varicella Zoster Infection Treatment Market Forecast, By Drug Type
12.22.1. Acyclovir
12.22.2. Valacyclovir
12.22.3. Famciclovir
12.23. Rest of Asia Pacific Varicella Zoster Infection Treatment Market Forecast, By Route of Administration
12.23.1. oral
12.23.2. Topical
12.23.3. Injectable
12.24. Asia Pacific Varicella Zoster Infection Treatment Market Attractiveness Analysis
12.24.1. By Drug Type
12.24.2. By Route of Administration
12.25. PEST Analysis
12.26. Key Trends
12.27. Key Developments

13. Middle East & Africa Varicella Zoster Infection Treatment Market Analysis
13.1. Key Findings
13.2. Middle East & Africa Varicella Zoster Infection Treatment Market Overview
13.3. Middle East & Africa Varicella Zoster Infection Treatment Market Value Share Analysis, By Drug Type
13.4. Middle East & Africa Varicella Zoster Infection Treatment Market Forecast, By Drug Type
13.4.1. Acyclovir
13.4.2. Valacyclovir
13.4.3. Famciclovir
13.5. Middle East & Africa Varicella Zoster Infection Treatment Market Forecast, By Route of Administration
13.5.1. oral
13.5.2. Topical
13.5.3. Injectable
13.6. Middle East & Africa Varicella Zoster Infection Treatment Market Value Share Analysis, by Country
13.7. Middle East & Africa Varicella Zoster Infection Treatment Market Forecast, by Country
13.7.1. GCC Countries
13.7.2. South Africa
13.7.3. Nigeria
13.7.4. Egypt
13.7.5. Rest of Middle East & Africa
13.8. Middle East & Africa Varicella Zoster Infection Treatment Market Analysis, by Country
13.9. GCC Countries Varicella Zoster Infection Treatment Market Forecast, By Drug Type
13.9.1. Acyclovir
13.9.2. Valacyclovir
13.9.3. Famciclovir
13.10. GCC Countries Varicella Zoster Infection Treatment Market Forecast, By Route of Administration
13.10.1. oral
13.10.2. Topical
13.10.3. Injectable
13.11. South Africa Varicella Zoster Infection Treatment Market Forecast, By Drug Type
13.11.1. Acyclovir
13.11.2. Valacyclovir
13.11.3. Famciclovir
13.12. South Africa Varicella Zoster Infection Treatment Market Forecast, By Route of Administration
13.12.1. oral
13.12.2. Topical
13.12.3. Injectable
13.13. Nigeria Varicella Zoster Infection Treatment Market Forecast, By Drug Type
13.13.1. Acyclovir
13.13.2. Valacyclovir
13.13.3. Famciclovir
13.14. Nigeria Varicella Zoster Infection Treatment Market Forecast, By Route of Administration
13.14.1. oral
13.14.2. Topical
13.14.3. Injectable
13.15. Egypt Varicella Zoster Infection Treatment Market Forecast, By Drug Type
13.15.1. Acyclovir
13.15.2. Valacyclovir
13.15.3. Famciclovir
13.16. Egypt Varicella Zoster Infection Treatment Market Forecast, By Route of Administration
13.16.1. oral
13.16.2. Topical
13.16.3. Injectable
13.17. Rest of Middle East & Africa Varicella Zoster Infection Treatment Market Forecast, By Drug Type
13.17.1. Acyclovir
13.17.2. Valacyclovir
13.17.3. Famciclovir
13.18. Rest of Middle East & Africa Varicella Zoster Infection Treatment Market Forecast, By Route of Administration
13.18.1. oral
13.18.2. Topical
13.18.3. Injectable
13.19. Middle East & Africa Varicella Zoster Infection Treatment Market Attractiveness Analysis
13.19.1. By Drug Type
13.19.2. By Route of Administration
13.20. PEST Analysis
13.21. Key Trends
13.22. Key Developments

14. South America Varicella Zoster Infection Treatment Market Analysis
14.1. Key Findings
14.2. South America Varicella Zoster Infection Treatment Market Overview
14.3. South America Varicella Zoster Infection Treatment Market Value Share Analysis, By Drug Type
14.4. South America Varicella Zoster Infection Treatment Market Forecast, By Drug Type
14.4.1. Acyclovir
14.4.2. Valacyclovir
14.4.3. Famciclovir
14.5. South America Varicella Zoster Infection Treatment Market Forecast, By Route of Administration
14.5.1. oral
14.5.2. Topical
14.5.3. Injectable
14.6. South America Varicella Zoster Infection Treatment Market Value Share Analysis, by Country
14.7. South America Varicella Zoster Infection Treatment Market Forecast, by Country
14.7.1. Brazil
14.7.2. Colombia
14.7.3. Argentina
14.7.4. Rest of South America
14.8. South America Varicella Zoster Infection Treatment Market Analysis, by Country
14.9. Brazil Varicella Zoster Infection Treatment Market Forecast, By Drug Type
14.9.1. Acyclovir
14.9.2. Valacyclovir
14.9.3. Famciclovir
14.10. Brazil Varicella Zoster Infection Treatment Market Forecast, By Route of Administration
14.10.1. oral
14.10.2. Topical
14.10.3. Injectable
14.11. Colombia Varicella Zoster Infection Treatment Market Forecast, By Drug Type
14.11.1. Acyclovir
14.11.2. Valacyclovir
14.11.3. Famciclovir
14.12. Colombia Varicella Zoster Infection Treatment Market Forecast, By Route of Administration
14.12.1. oral
14.12.2. Topical
14.12.3. Injectable
14.13. Argentina Varicella Zoster Infection Treatment Market Forecast, By Drug Type
14.13.1. Acyclovir
14.13.2. Valacyclovir
14.13.3. Famciclovir
14.14. Argentina Varicella Zoster Infection Treatment Market Forecast, By Route of Administration
14.14.1. oral
14.14.2. Topical
14.14.3. Injectable
14.15. Rest of South America Varicella Zoster Infection Treatment Market Forecast, By Drug Type
14.15.1. Acyclovir
14.15.2. Valacyclovir
14.15.3. Famciclovir
14.16. Rest of South America Varicella Zoster Infection Treatment Market Forecast, By Route of Administration
14.16.1. oral
14.16.2. Topical
14.16.3. Injectable
14.17. South America Varicella Zoster Infection Treatment Market Attractiveness Analysis
14.17.1. By Drug Type
14.17.2. By Route of Administration
14.18. PEST Analysis
14.19. Key Trends
14.20. Key Developments

15. Company Profiles
15.1. Market Share Analysis, by Company
15.2. Competition Matrix
15.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications, and R&D investment
15.2.2. New Product Launches and Product Enhancements
15.2.3. Market Consolidation
15.2.3.1. M&A by Regions, Investment and Applications
15.2.3.2. M&A Key Players, Forward Integration and Backward Integration
15.3. Company Profiles: Key Players
15.3.1. Dr. Reddy’s Laboratories Ltd.
15.3.1.1. Company Overview
15.3.1.2. Financial Overview
15.3.1.3. Product Portfolio
15.3.1.4. Business Strategy
15.3.1.5. Recent Developments
15.3.1.6. Development Footprint
15.3.2. Pfizer Inc.
15.3.3. Abbott Laboratories
15.3.4. Teva Pharmaceutical Industries Ltd.
15.3.5. Mylan N.V.
15.3.6. Sun Pharmaceuticals
15.3.7. Valeant pharmaceuticals
15.3.8. Novartis AG
15.3.9. GlaxoSmithKline Plc.
15.3.10. Bausch health
15.3.11. Merck Sharp & Dohme corp.

16. Primary key Insights
  • INQUIRE BEFORE BUYING